Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 6/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918531 | 0.89 | PDE2A (0.32) | PDE3BPDE3AP2RY12JAK3JAK2 | |
| SCHEMBL9921765 | 0.71 | TTBK1 (0.40) | PDE3BPDE3AP2RY12CCNCCDK8 | |
| SCHEMBL9921741 | 0.69 | ESR1 (0.38) | JAK3JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL12832974 | 0.69 | TTBK1 (0.39) | PDE3BPDE3AP2RY12CCNCCDK8 | |
| SCHEMBL9921664 | 0.68 | MAP3K11 (0.41) | JAK3JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL9918533 | 0.67 | MAP3K11 (0.41) | JAK3JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL9918534 | 0.67 | TSHR (0.35) | JAK3JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL22434609 | 0.64 | LTA4H (0.49) | CCNCCDK8PDK2 | |
| SCHEMBL9923069 | 0.64 | L3MBTL1 (0.66) | CCNCCDK8HTTPDK2 | |
| SCHEMBL9918551 | 0.62 | MAP3K11 (0.35) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | PDE3B 1021/4885PDE3A 1414/4885P2RY12 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.